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Abstract To examine immune-inflammatory and oxidative
(I&O) biomarkers in major depression (MDD) and its related
phenotypes, we recruited 114 well-phenotyped depressed pa-
tients and 50 healthy controls and measured serum levels of
interleukin (IL)-1α, soluble IL-1 receptor antagonist (sIL-
1RA), soluble IL-2 receptor (sIL-2R), soluble IL-6 receptor
(sIL-6R), soluble tumor necrosis factor receptor 60 and
80 kDa (sTNF-R1/R2), and thiobarbituric acid reactive sub-
stances (TBARS). Obtained results indicate that MDD is char-
acterized by increased sIL-1RA, sTNF-R1, and TBARS con-
centrations. Melancholic depression is associated with in-
creased sIL-6R but lowered IL-1α levels. A current episode
of depression is accompanied by significantly increased sIL-
6R compared to the remitted state. Treatment-resistant depres-
sion (TRD) is accompanied by increased sIL-6R and TBARS
but lowered sTNF-R2 levels compared to non-TRD patients.
These immune markers are not significantly correlated with
Hamilton Depression Rating Scale (HDRS), Montgomery-
Asberg Depression Scale (MADRS), number episodes, or
age at onset. Our findings show that increased sIL-1RA,
sTNF-R1, and TBARS levels may be trait markers of depres-
sion, while increased sIL-6R levels may be a state marker of
melancholia and an acute phase of depression. MDD is ac-
companied by increased lipid peroxidation and simultaneous
activation of immune pathways, and the compensatory anti-
inflammatory reflex system (CIRS). TRD is characterized by
highly increased oxidative stress and probably increased
TNFα and IL-6 trans-signalling. Novel treatments for major
depression should target oxidative stress pathways, while new
treatments for TRD should primary target lipid peroxidation
and also activated immune-inflammatory pathways.
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Introduction
Already in the 1990s, it was shown that major depression
(MDD) is accompanied by an immune response and Thelper
(Th)1 activation as indicated by elevated serum levels of sol-
uble interleukin (IL)-2 receptor (sIL-2R), increased expression
of activation markers on peripheral blood mononuclear cells
(PBMCs), e.g., Human Leukocyte Antigen-antigen D Related
(HLA-DR) and cluster of differentiation 25 (CD25), resis-
tance of cytokine production by immune cells to dexametha-
sone administration, and increased stimulated production of
interferon (IFN)γ (Maes et al. 1990, 1991, 1992a, 1994;
Seidel et al. 1995). Simultaneously, it was shown that major
depression is accompanied by a chronic low-grade inflamma-
tory response as indicated by increased levels of macrophage
M1-related pro-inflammatory cytokines, including IL-1β and
tumor necrosis factor (TNF)α, the soluble IL-1 receptor an-
tagonist (sIL-1RA), increased IL-6 trans-signaling (that is in-
creased IL-6 and sIL-6R levels), and increases in positive
acute phase proteins, such as haptoglobin, and complement
factors (Maes et al. 1991, 1992b, 1994, 1995a, b; Słuzewska
et al. 1995; Frommberger et al. 1997; Mikova et al. 2001).
Activation of immune-inflammatory pathways in major de-
pression has now been consolidated in meta-analysis studies
indicating increased IL-6, TNFα, sIL-2R, IL-1β, sIL-1RA,
and C-reactive protein (CRP) levels in major depression
(Howren et al. 2009; Dowlati et al. 2010; Liu et al. 2012;
Hiles et al. 2012; Valkanova et al. 2013; Haapakoski et al.
2015; Köhler et al. 2017). These meta-analyses showed addi-
tionally that Th2 and Tregulatory (Treg) cytokines (including
IL-10, IL4, and IL-5) were not significantly altered in major
depression indicating that major depression is characterized
by M1 and Th1 activation. There are also some reports that
plasma levels of soluble TNF receptor 60 kDa (sTNF-R1) and
80 kDa (sTNF-R2) are elevated in depression (Grassi-Oliveira
et al. 2009; Moughrabi et al. 2014; Rizavi et al. 2016). These
TNFα receptor subtypes act as decoy receptors by binding
sTNFα thereby attenuating TNFα signaling and thus
inhibiting TNFα activities (Selinsky et al. 1998; Su et al.
1998).
Other reports showed significant changes in immune-
inflammatory signature in clinical subtypes of major depres-
sion, most notably major depression with melancholic and
atypical features. For example, melancholia is characterized
by increased levels of acute phase proteins, e.g., haptoglobin,
expression of T cell activation markers and increased resis-
tance of IL-1β and sIL-2R production to dexamethasone ad-
ministration as compared to simple major depression (Maes
et al. 1991, 1992a, 1994). In major depression with atypical
features, lowered IL-4 but increased IL-2 concentrations were
observed, whereas no changes in IL-6 or TNFα concentra-
tions could be established (Yoon et al. 2012). The lack of
M1 activation in atypical depression was further substantiated
by findings of Dunjic-Kostic et al. (2013) who showed that
IL-6 was significantly increased in melancholic depression
but not in atypical depression. These results may suggest that
there is a difference in cytokine signature between melanchol-
ic and atypical depression the former being associated with
M1 and Th1 activation and the latter with a Th1 shift away
from Th2 (Maes 2011; Yoon et al. 2012).
Moreover, differences in immune-inflammatory signature
were observed in clinical subgroups divided according to stag-
ing characteristics, including acute versus remission phase of
depression. Thus in vivo, antidepressant treatments, especially
with selective serotonin reuptake inhibitors (SSRIs), reduce
IL-1β, CRP, and (maybe) IL-6 levels (Maes et al. 1995a;
Hannestad et al. 2011; Hiles et al. 2012). Nevertheless, not
all papers found a reduction of these immune-inflammatory
biomarkers after treatment and could find significant differ-
ences between patients in an acute phase of depression and
those who were euthymic (Maes 2011), suggesting that in-
creased levels of cytokines (including IL-6 and sIL-6R) are
trait markers of major depression. There is also some evidence
that treatment-resistant depression (TRD) is characterized by
specific immune biomarkers, including increased IL-6, sIL-
1RA, and TNFα concentrations (Maes et al. 1997;
Lanquillon et al. 2000).
Major depression is accompanied by activated oxidative
stress pathways as indicated by increased lipid peroxidation,
oxidative damage to DNA and mitochondrial functions, oxi-
dative damage to membranes, including increased expression
of neoantigens such as malondialdehyde (MDA) and oxidized
low-density lipoprotein (LDL), and lowered antioxidant levels
including zinc (review Maes et al. 2011; Liu et al. 2015;
Styczeń et al. 2017). There is some evidence that activated
immune-inflammatory and oxidative (I&O) pathways are in-
terrelated phenomena in depression (review Moylan et al.
2014). However, there are no data whether increased lipid
peroxidation is associatedwith subtypes of depression, includ-
ing TRD or melancholia.
This study was performed to examine immune and ox-
idative biomarkers (namely IL-1α, sIL-1RA, sIL-2R, sIL-
6R, sTNF-R1, sTNF-R2, and thiobarbituric acid reactive
substances—TBARS), a surrogate marker of MDA pro-
duction, in major depression and to examine whether
these measurements may be state or trait markers of de-
pression, clinical subtypes of depression (including mel-
ancholia and atypical depression), or treatment resistance.
Here we measure serum concentrations of cytokine recep-
tors (sIL-1RA, sIL-2R, sIL-6R, sTNF-R1, sTNF-R2),
rather than their cytokine counterparts (except IL-1α) be-
cause measurements of the receptor levels are more reli-
able, while showing higher levels than cytokines which
are often not detectable in peripheral blood (e.g., IL-2).
We were also interested in IL-1α levels as many papers in
depression focused on IL-1β while neglecting IL-1α
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(Maes et al. 2012c). Finally, we have measured TBARS
as a surrogate biomarker of lipid peroxidation.
Subjects and Methods
Subjects
This case-control study included major depressed patients
(n = 114) and healthy controls (n = 50) during the period 21
September 2009 to 30 July 2013. All patients were in- or
outpatients in an acute or remission phase of illness and were
recruited at the Department of Psychiatry of the University
Hospital in Krakow, Krakow, Poland. A psychiatrist made
the axis I DSM-IV-TR diagnosis using the semi-structured
clinical interview for DSM-IV interview (SCID) axis I disor-
ders (American Psychiatric Association 2000). Diagnosis of
melancholic syndrome was based on DSM-IV-TR criteria of
major depression episode with melancholic features. The con-
trols were recruited by word of mouth from hospital staff and
relatives and friends of hospital staff. In this study, we includ-
ed male and female subjects of Polish (Caucasian) ethnicity,
both sexes and aged 21–70 years. We excluded individuals
with (a) axis II personality disorders; (b) psychiatric diagnoses
other thanmajor depression, e.g., bipolar disorder, schizophre-
nia, psychoactive substance dependence (all except nicotine
dependence); (c) obesity, that is with a body mass index
(BMI) > 30; (d) medical diseases such as primary adrenocor-
tical insufficiency, (auto)immune diseases, renal failure,
chronic pancreatitis, primary hypoaldosteronism, carcinomas,
hypoparathyroidism, hyperthyroidism, megaloblastic anemia
due to iron deficiency, thalasemia, hemochromatosis, liver
cirrhosis, Wilson’s disease, nephrotic syndrome and burns;
and (e) infections and acute inflammatory responses within a
month before the study. We also excluded subjects using non-
steroidal anti-inflammatory drugs, e.g., acetylsalicylic acid,
ibuprophen, indomethacin; hydralazine; tetracyclines;
fluorochinolones; calcium; iron; chelating agents or
glucocorticosteroids; and breast feeding and pregnant women.
Healthy controls were excluded for life-time axis I/II diagno-
ses, including major depression, and for a family history of
depression, (hypo)mania, alcohol dependence, and suicidal
behaviors. The depressed patients were treated with mono-
therapy or combinatorial treatments, i.e., SSRIs (n = 63), se-
lective noradrenaline reuptake inhibitors (SNRIs) (n = 34),
tricyclic antidepressants (TCAs) (n = 15), mirtazpine (n = 5),
atypical antipsychotics (n = 15), lithium (n = 3), and
lamotrigine (n = 2). Treatment-resistant depression was de-
fined as the absence of a therapeutic response to at least two
further pharmacotherapies with two successively used, differ-
ent antidepressants at an adequate dose and for an adequate
amount of time. The study was approved by the Bioethical
Committee of the Jagiellonian University, Krakow, Poland
(decision number KBET/77/B/2009; 25.06.2009) and all sub-
jects gave written informed consent prior to participating in
this study. The detailed socio-demographic and clinical char-
acteristics of the examined population were presented previ-
ously (Styczeń et al. 2015).
Methods
Severity of depression was measured with the Hamilton
Depression Rating Scale (HDRS) (Hamilton 1960) and the
Montgomery-Asberg Depression Rating Scale (MADRS)
(Montgomery and Asberg 1979). A semi-structured question-
naire was employed to screen for sociodemographic data (age,
gender, marital status) and clinical data (age at onset, number of
depressive episodes, use of drugs, and nicotine dependence).
Blood (9.8 mL) was sampled around 8.00 a.m. from a
brachial vein after an overnight fast. Forty-five minutes later,
blood was centrifuged at 1800×g for 30 min. Serum was con-
sequently stored at −80 °C until thawed for assay. The
cytokine/cytokine receptor biomarkers were determined by
enzyme-linked immunoassay (ELISA) using high sensitivity
commercially available kits (IL-1α—RayBiotech, Norcross,
GA, USA; sIL-1RA, sIL-2R, and sIL-6R—R&D Systems,
Minneapolis, MN, USA; sTNF-R1 and sTNF-R2—
eBioscience, Hatfield, UK) according to the manufacturers’
protocols. Briefly, appropriate volumes of standards and sam-
ples were dispensed into 96-well plates coated with human
anti-sIL-1RA, sIL-2R, sIL-6R, sTNF-R1, or sTNF-R2 anti-
bodies and incubated. After extensive washing, an enzyme-
linked polyclonal antibody specific for examined proteins was
added and incubated. Following a wash to remove any un-
bound antibody-enzyme reagent, a substrate solution was pi-
petted to the wells and color develops in proportion to the
amount of specific protein bound in the initial step. The reac-
tion was stopped by adding a stop solution, and the absor-
bance was determined at a wavelength of 450 nm. Lipid per-
oxidation levels were measured using TBARS Assay kit
(Cayman Chemical, Ann Arbor, MI, USA) according to the
manufacturer’s recommendations. In this method, MDA re-
acts with thiobarbituric acid (TBA) under high temperature
(90–100 °C) and acidic conditions, generating the MDA-
TBA adduct. The MDA-TBA adduct was determined
fluorometrically at an excitation wavelength of 530 nm and
an emission wavelength of 550 nm. All the measurements
were performed using the Synergy 2 multi-mode microplate
reader and Gen5 Software (BioTek, Winooski, VT, USA). All
assays were performed in duplicate. The detection limits were
IL-1α of 0.412 pg/mL, sIL-1RA 18.3 pg/mL, sIL-2R 10 pg/
mL, sIL-6R 15.1 pg/mL, sTNF-R1 0.05 ng/mL, sTNF-R2
0.10 ng/mL, and TBARS 0.0625 nmol/mL. The intra- and
inter-assay coefficients of variation were < 7.5% for all
analytes.
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Statistics
Analyses of variance (ANOVAs) were employed to check
differences in sociodemographic, clinical and biomarker data
between diagnostic groups, and analyses of contingency ta-
bles (Χ2 tests) to assess associations between nominal vari-
ables. Correlations were calculated using Pearson’s product
moment correlation coefficients and stepwise automatic uni-
variate regression analysis. We used automatic stepwise bina-
ry regression analysis to delineate the significant explanatory
variables predicting major depression (versus controls) or
melancholic depression (versus no melancholia) as dependent
variables. We employed multivariate general linear model
(GLM) analysis with the immune markers as dependent vari-
ables and diagnoses as explanatory variables, while adjusting
for other background variables including age, sex, and drug
status. Consequently, we used tests for between-subjects ef-
fects to assess which dependent variables were significantly
associated with the significant explanatory variables.
Estimated marginal mean values (standard error; SE) obtained
by GLM analysis were used to interpret differences among the
groups based on protected least significant differences (LSD).
Principal component (PC) analysis was used as a data reduc-
tion method to create one or two composite factors that reflect
use of psychotropic drugs (e.g., SSRIS, SNRIs, TCAs, and
atypical antipsychotics), namely the first or first two interpret-
able PCs generated by PC analysis, whereby the number of
PCs is based on eigenvalues > 1. For interpretation purposes,
we employed varimax rotation and entered the varimax-
rotated PC scores in statistical analyses including multivariate
GLM and binary regression analyses as indexes of drug use.
We employed Ln transformations of the biomarker data to
normalize the data distribution (checked with Kolmogorov-
Smirnov test). We used the IBM-SPSS windows version 22
to analyze all data. All tests were two-tailed and a p value of
0.05 was used for statistical significance.
Results
Table 1 shows the sociodemographic, biomarker, and clinical
data in healthy controls and depressed patients with and with-
out treatment resistance. There were no significant differences
in age, sex ratio, and marital status between the three groups.
Nicotine dependence was significantly higher in patients with
and without TRD than in normal controls. ANOVA showed
significantly higher sIL-1RA levels in depressed patients than
in controls and lowered sTNF-R2 levels in depressed patients
with TRD than in those without. ANOVA showed that the
TBARS levels were significantly different between the three
study groups. There were no significant differences in HDRS
and MADRS scores, age at onset, number of episodes, and
presence of melancholia or atypical depression and a current
episode between subjects with and without treatment resis-
tance. We did not employ p-corrections to ascertain the results
of these multiple ANOVAs/Χ2 tests in Table 1 because these
results of univariate tests were used to define the explanatory
variables that will be employed as determinants of indepen-
dent association in the ultimate multivariate GLM analyses.
Table 2 shows the results of multivariate GLM analyses
performed in the depressed patients only. Immune biomarkers
and TBARS data were entered as dependent variables and
diagnostic groups (depression with and without TRD) as ex-
planatory variables, while adjusting for age, sex, nicotine de-
pendence, and drug use variables, which were entered as the
first two PCs subtracted from four drug state variables. Thus,
the first varimax-rotated PC (PC1) explained 43.97% of the
variance and loaded highly (> 0.800) on SSRIs (negatively)
and SNRIs (positively). The second varimax-rotated PC
(PC2) explained 28.3% of the variance and loaded highly
(> 0.600) on use of triclyclic antidepressants (negatively)
and atypical antipyschotics (positively). We found significant
effects of diagnosis, age, and nicotine dependence, but not
sex, PC1, and PC2 on the biomarkers. Tests for between-
subject effects showed that diagnosis had significant effects
on sIL-6R, sTNF-R2, and TBARS levels; age on sTNF-R1
(positive association) and sTNF-R2 (negative association);
and nicotine dependence on IL-1α and sIL-2R levels. The
second multivariate GLM analysis used the same dependent
and explanatory variables but was performed on all subjects
and therefore considered the effects of three groups, i.e., con-
trols and depression with and without TRD. We found signif-
icant multivariate effects of diagnosis and nicotine depen-
dence but not age, sex, PC1, and PC2. Tests of between-
subject effects showed significant associations between diag-
nosis and sIL-1RA, sIL-6R, sTNF-R1, and TBARS levels.
Table 3 shows the adjusted means (after adjusting for age,
sex, and drug state) of the biomarkers and results of protected
LSDs. sIL-1RA levels were higher in depressed patients with-
out treatment resistance than in controls. sIL-6R levels were
higher in patients with treatment resistance than in controls
and patients without treatment resistance. sTNF-R2 values
were significantly lower in controls and patients with treat-
ment resistance than in patients without treatment resistance.
TBARS levels were significantly different between the three
subgroups and increased from controls to non-TRD to TRD.
Figure 1 shows the mean (SE) values of the z scores of the ln
transformed immune measurements.
Table 4 shows the results of an automatic stepwise
regression analysis with depression as dependent variable
(and controls as reference group) and all seven bio-
markers, age, and sex as explanatory variables. We found
three significant biomarkers (Χ2 = 31.78, df = 3,
p < 0.001; Nagelkerke = 0.303) which were positively
associated with major depression, i.e., sIL-1RA, TNF-
R1, and TBARS levels. Of the subjects, 74.2% were
Neurotox Res (2018) 33:448–460 451
correctly classified with a sensitivity of 75.0% and a spec-
ificity of 72.5%.
Table 5 shows the results of a multivariate GLM analysis
performed on all subjects with the seven biomarkers as depen-
dent variables and with diagnosis, i.e., a current episode ver-
sus remission and controls, as explanatory variable, while
adjusting for age, sex, nicotine dependence, and drug state
as covariates. Tests of between-subject effects show signifi-
cant effects of diagnosis on sIL-1RA, sIL-6R, and TBARS
values. Table 6 shows the adjusted means (after adjusting for
age, sex, and drug state) of these three biomarkers and results
of protected LSDs. sIL-1RA levels were significantly higher
in both depression groups than in controls. sIL-6R values were
significantly higher in an acute phase of depression as com-
pared to controls and patients in remission. TBARS levels
were significantly higher in both depression groups than in
healthy controls. We also examined the associations of the
biomarkers and atypical depression by entering diagnosis as
three groups, i.e., depression with and without atypical fea-
tures and controls, in a multivariate GLM analysis (Table 5).
We could not find any differences between atypical and non-
atypical depression in the biomarkers. There were only
significant differences between controls and depressed pa-
tients. We also examined the associations of the seven bio-
markers with melancholia by entering diagnosis as three
groups, namely depression with and without melancholia
and controls in a multivariate GLM analysis. However, be-
cause we found that the use of psychotropic drugs (PC2)
was associated with melancholia, we did not interpret this
GLM analysis but examined the characteristics of melancholic
depression using a binary logistic regression analysis with
melancholia as dependent variable (see Table 7). Table 5 also
shows the possible associations between the seven biomarkers
and clinical variables, including HDRS and MADRS. There
were no significant associations between any of the bio-
markers and HDRS and MADRS scores, number of episodes
and age at onset of depression.
Table 7 shows the outcome of an automatic stepwise logis-
tic regression analysis with melancholic depression as depen-
dent variable (and non-melancholic depression as reference
group) and the seven biomarkers as explanatory variables
and with forced entry of PC1 and PC2. Two biomarkers and
PC2 were significant in this regression analysis (Χ2 = 37.2,
df = 4, p < 0.001, Nagelkerke = 0.372). IL-1α (inversely) and
Table 1 Sociodemographic,
clinical, and biomarker data in
patients with treatment-resistant
depression (TRD), non-TRD, and
healthy controls (HC)
Variables HCA (n = 50) Non-TRDB
(n = 72)
TRDC
(n = 42)
F/O2 df p
Age (years) 45.8 (12.4) 48.9 (11.9) 50.2 (8.5) 1.89 2/131 0.155
Gender (F/M) 34/14 42/30 31/11 3.84 2 0.147
Marital status* 18/29 17/55 7/33 5.34 2 0.069
Nicotine dependence
(N/Y)
47/3 38/33 21/21 26.76 2 < 0.001
IL-1α (pg/mL) 2.7 (2.4) 2.3 (1.8) 4.9 (10.8) 0.31 2/155 0.732
IL-1RA (ng/mL) 3.30 (2.45)B,
C
5.30 (3.94) A 5.23 (3.17)A 5.61 2/155 0.004
IL-2R (pg/mL) 783 (385) 919 (458) 829 (298) 1.19 2/157 0.308
IL-6R (ng/mL) 26.6 (9.4) 25.8 (6.3) 36.3 (34.8) 2.95 2/150 0.056
sTNF-R1 (ng/mL) 0.18 (0.07) 0.20 (0.006) 0.23 (0.22) 1.71 2/143 0.184
sTNF-R2 (ng/mL) 1.01 (1.32) 0.98 (0.99)C 0.84 (1.55)B 4.03 2/139 0.020
TBARS (nmol/mL) 2.37 (1.10)
B,C
3.18 (1.22)A, C 3.86
(1.42)A,B
15.34 2/154 < 0.001
HDRS – 12.2 (8.5) 14.3 (9.7) 1.40 1/112 0.239
MADRS – 16.5 (13.2) 19.2 (13.7) 1.06 1/112 0.305
Age at onset (years) – 35.5 (12.7) 37.2 (11.0) 0.53 1/110 0.466
Number episodes – 5.6 (4.2) 6.0 (4.5) 0.53 1/107 0.612
Melancholia (no/yes) – 49/22 25/15 0.49 1 0.485
Atypical MDD (no/yes) – 62/10 29/11 3.13 1 0.087
Current MDD (no/yes) – 40/29 32/13 2.02 1 0.155
Data are shown as mean (standard deviation; SD). Superscript A, B, C show the significant (p = 0.05) pairwise
differences among the three study samples
IL-1α interleukin-1 alpha, sIL-1RA soluble interleukin 1 receptor antagonist, sIL-2R soluble interleukin 2 receptor,
sIL-6R soluble interleukin 6 receptor, sTNF-R1/R2 soluble tumor necrosis factor receptor 60 kDa/80 kDa, TBARS
thiobarbituric acid reactive substances
*Marital status: stable relationship + married / single + divorced
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sIL-6R (positively) were significantly associated with melan-
cholia. The positive association betweenmelancholia and PC2
indicates that more patients with melancholia were treated
with atypical antipsychotics. Figure 2 shows the mean (SE)
values of the z scores of the ln transformed immune
measurements.
The relationships between TBARS and the immune-
inflammatory biomarkers were first examined using correla-
tion analyses. Thus, TBARS was significantly correlated with
sIL-1RA (r = 0.201, p = 0.012, n = 155) and sIL-6R
(r = 0.210, p = 0.010, n = 150), but not IL-1α (r = 0.144,
p = 0.076, n = 153), sIL-2R (r = −0.058, p = 0.470, n = 157),
Table 2 Results of multivariate
GLM analyses with the six
cytokine biomarkers [interleukin
(IL)-1α, soluble interleukin 1
receptor antagonist (sIL-1RA),
soluble interleukin 2 receptor
(sIL-2R), soluble interleukin 6
receptor (sIL-6R), soluble tumor
necrosis factor receptor 60 kDa /
80 kDa (sTNF-R1/2)] and thio-
barbituric acid reactive substances
(TBARS) as dependent variables
and diagnostic groups, age, gen-
der, marital status, and nicotine
dependence as explanatory
variables
Tests Dependent
variables
Explanatory
variables
F df p
(1) Multivariate analysis in MDD patients 7 biomarkers TRD vs
non-TRD
Age
Sex
TUD
PC1
PC2
2.33
3.52
0.77
2.76
1.50
0.62
7/64 0.035
0.003
0.619
0.014
0.184
0.735
Between-subject effects sIL-6R
sTNF-R2
TBARS
TRD vs
non-TRD
TRD vs
non-TRD
TRD vs
non-TRD
5.24
4.66
5.12
1/70 0.025
0.034
0.027
Between-subject effects sTNF-R1
sTNF-R2
Age (+)
Age (−)
7.78
8.86
1/70 0.007
0.004
Between-subject effects IL-1α
sIL-2R
TUD
TUD
5.54
0.74
1/70 0.021
0.002
(2) Multivariate analysis in MDD patients
and controls
7 biomarkers TRD, non-TRD,
HC
Age
Sex
TUD
PC1
PC2
3.31
2.01
1.04
2.71
1.38
0.88
14/208
7/103
7/103
7/103
7/103
7/103
< 0.001
0.061
0.406
0.013
0.224
0.523
Between-subject effects sIL-1RA
sIL-6R
sTNF-R2
TBARS
TRD, non-TRD,
HC
TRD, non-TRD,
HC
TRD, non-TRD,
HC
TRD, non-TRD,
HC
4.37
3.06
3.27
9.85
2/109 0.015
0.051
0.042
< 0.001
Results of two different multivariate GLM analyses (with tests for between-subject effects) considering the effects
of diagnostic groups entered as (1) two groups, i.e., TRD versus non-TRD; or (2) three groups, i.e., TRD versus
non-TRD versus healthy controls (HC)
Table 3 Marginal means (SE)
obtained by GLM analyses in the
second multivariate GLM analy-
ses with HC, TRD, and non-TRD
as groups
Biomarkers HCA Non-TRDB TRDC
Ln sIL-1RA (ng/mL) 7.83 (0.14)B 8.33 (0.11)A 8.20 (0.15)
Ln sIL-6R (ng/mL) 10.08 (0.07)C 10.11 (0.05)C 10.30 (0.07)A, B
Ln sTNF-R2 (ng/mL) − 0.57 (0.14)B − 0.19 (0.10)A, C − 0.52 (0.15)B
Ln TBARS (nmol/mL) 0.77 (0.09)B,C 1.10 (0.06)A, C 1.33 (0.09)A, B
A, B, C Shows the significant (p = 0.05) pairwise differences among the three study samples
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sTNF-R1 (r = −0.111, p = 0.184, n = 145), and sTNF-R2
(r = −0.134, p = 0.114, n = 141). Secondly, we used a univar-
iate automatic stepwise regression analysis to examine the
correlations between TBARS and the six immune markers,
age, sex, TUD, and PC1 and PC2. Of the variance in
TBARS, 11.7% (F = 4.40, df = 4/131, p = 0.002) was ex-
plained by the regression on TNF-R1 (t = − 2.20,
p = 0.028), sIL-1RA (t = + 2.11, p = 0.036), TUD (t = +
2.26, p = 0.025), and sex (t = + 2.37, p = 0.019).
Discussion
A first major finding of this study is that major depressive
disorder is accompanied by increased sIL-1RA, TNF-R1,
and TBARS concentrations as compared to normal controls.
The sIL-1RA results are in agreement with previous findings
showing that depression or depressive phenomenology is ac-
companied by increased levels of sIL-1RA (Maes et al. 1995b,
2012c; Song et al. 1998; Rief et al. 2001; Ruiz et al. 2007;
Milaneschi et al. 2009; Ovaskainen et al. 2009; Lehto et al.
2010; Dahl et al. 2014). mRNA levels of IL-1RA are signif-
icantly higher in lymphocytes of depressed patients compared
with controls (Rizavi et al. 2016). Meta-analysis studies
showed increased sIL-1RA levels in major depression
(Howren et al. 2009; Goldsmith et al. 2016). Previous research
also showed increased mitogen-stimulated IL-1β production
and lymphocyte IL-1β mRNA levels in major depression
(Maes et al. 1991; Rizavi et al. 2016). IL-1RA production is
stimulated in IL-1 expressing cells (including monocytes, ep-
ithelial cells, adipocytes, keratinocytes, and hepatocytes), by
IL-1, viral products, some acute phase proteins, and molecular
cascades involving IL-6 and IL-4 (Sone et al. 1994; Kay and
Calabrese 2004; Perrier et al. 2006).While increased sIL-1RA
levels signal immune activation, this protein acts as an endog-
enous inhibitor of IL-1β and IL-1α activities thereby playing
an important role in the resolution of inflammation and tissue
repair in IL-1β-associated disorders (Arend and Guthridge
Fig. 1 The mean (SE) values of
all measurements in healthy con-
trols (0), patients with depression
without treatment resistance (1),
and those with treatment resis-
tance (2). All data are in z scores
computed on the Ln transforma-
tion of the measurements. IL-1α,
interleukin-1 alpha; IL-1RA, sol-
uble interleukin 1 receptor antag-
onist; IL-2R, soluble interleukin 2
receptor; IL-6R, soluble interleu-
kin 6 receptor; TNF-60/80, solu-
ble tumor necrosis factor receptor
60 kDa/80 kDa (R1/R2); TBARS,
thiobarbituric acid reactive
substances
Table 4 Results of automatic logistic regression analyses with major
depression (MDD) versus healthy controls as dependent variable and the
immune biomarkers, i.e., interleukin-1α, soluble interleukin 1 receptor
antagonist (sIL-1RA), sIL-2R, sIL-6R, soluble tumor necrosis factor
receptor 60 kDa/80 kDa (sTNF-R1/R2), and thiobarbituric acid reactive
substances (TBARS), age, gender, nicotine dependence, education, mar-
ital status as explanatory variables
Dependent variables Explanatory variables Wald df p Odds ratio lower and upper 95% CI
MDD (versus controls) sIL-1RA
sTNF-R1
TBARS
4.25
4.08
16.39
1
1
1
0.039
0.043
< 0.001
1.83
3.58
7.43
1.03–3.26
1.04–12.37
2.81–19.62
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2000). As such, increased levels of sIL-1RA are part of the
compensatory (anti)inflammatory reflex system (CIRS),
which tends to attenuate an overzealous immune-
inflammatory response, including increased IL-1β signaling
(Maes et al. 2012a).
Our findings that depression is accompanied by increased
sTNF-R1 levels are in agreement with results of Grassi-
Oliveira et al. (2009). Moreover, in patients with heart failure,
elevated sTNF-R1 levels increase risk of depression
(Moorman et al. 2007). Rizavi et al. (2016) detected increased
TNF-R1 mRNA levels in lymphocytes of depressed patients
as compared with normal volunteers. Increased sTNF-R1
levels were also established in bipolar depression (Barbosa
et al. 2011; Teixeira et al. 2015). In fact, sTNF-R1 levels
may be higher in bipolar disorder than in major depression
(Bai et al. 2015). In our study, we found that non-TRD de-
pression was accompanied by significantly higher levels of
sTNF-R2 levels as compared with controls and those with
TRD, thus indicating that sTNF-R2 levels may be increased
in major depression. Previously, it was shown that depression
is accompanied by increased sTNF-R2 levels (Grassi-Oliveira
et al. 2009), while sTNF-R2 levels are also elevated in late life
depression (Diniz et al. 2010). In patients with stable heart
failure, increased sTNF-R2 levels are associated with an in-
creased risk of depression (Moughrabi et al. 2014). In the
Rizavi et al. (2016) study, depression was not only accompa-
nied by increased lymphocytic sTNF-R1, but also sTNF-R2
mRNA levels. Increased serum levels of TNFα in major de-
pression were first described by Mikova et al. (2001) and
confirmed by a meta-analysis (Liu et al. 2012). The inflam-
matory effects of TNFα are mediated by cell surface-bound
receptors (TNF-R1 and TNF-R2), which may be released in
the plasma to exert negative regulatory functions on TNFα
signaling (Sedger and McDermott, 2014). Increased levels of
both serum soluble receptor subtypes, which act as decoy
receptors, may indicate increased negative immune regulation
Table 5 Results of GLM
analyses with the six immune
biomarkers, i.e., interleukin-1α,
soluble interleukin 1 receptor
antagonist (sIL-1RA), sIL-2R,
sIL-6R, soluble tumor necrosis
factor receptor 60 kDa/80 kDa
(sTNF-R1/R2), and thiobarbituric
acid reactive substances
(TBARS) as dependent variables
and diagnostic groups, age, gen-
der, marital status, and nicotine
dependence as explanatory
variables
Tests Dependent
variables
Explanatory
variables
F df p
Multivariate analysis in all subjects 7 biomarkers Current, no-current
Age
Sex
TUD
PC1
PC2
2.74
1.76
0.92
2.48
1.59
0.98
14/208
7/103
7/103
7/103
7/103
7/103
0.001
0.103
0.497
0.022
0.148
0.447
Between-subject analyses sIL-1RA
sIL-6R
TBARS
HC, current,
no-current
HC, current,
no-current
HC, current,
no-current
4.19
4.68
8.10
2/109
2/109
2/109
0.018
0.011
0.001
Multivariate analysis in all subjects 7 biomarkers HC, atypical, no
atypical
2.96 14/242 < 0.001
Multivariate analysis in all subjects 7 biomarkers HC, MEL, no MEL 2.94 14/242 < 0.001
Multivariate analysis in depressed
subjects
7 biomarkers HDRS
MADRS
Number episodes
Age at onset
PC1
PC2
0.80
0.49
0.59
1.56
1.53
0.64
7/81
7/81
7/76
7/80
7/65
7/65
0.598
0.840
0.764
0.160
0.174
0.725
HC, current, non-current: diagnostic groups are entered as three groups, healthy controls (HC), current depression,
and no-current depression
Table 6 Marginal means (SE)
obtained by GLM analyses in the
second multivariate GLM analy-
ses with HC, current, and no-
current as groups
Biomarkers HCA Current MDDB No current MDD C
Ln sIL-1RA (pg/mL) 7.83 (0.14)B, C 8.28 (0.11)A 8.33 (0.13)A
Ln sIL-6R (pg/mL) 10.08 (0.07)B 10.26 (0.05)A, C 10.02 (0.07)B
Ln TBARS (nmol/mL) 0.77 (0.09)B, C 1.23 (0.07)A 1.09 (0.09)A
A, B, C Shows the significant (p = 0.05) pairwise differences among the three study samples
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on increased TNFα-mediated inflammatory signaling
(Selinsky et al. 1998; Su et al. 1998).
Increased levels of TBARS/MDA have repeatedly been
described in patients with depression (Gałecki et al. 2009;
Maes et al. 2013; Bajpai et al. 2014), although not all authors
were able to find such increases (Magalhães et al. 2012).
Nevertheless, a recent meta-analysis (Liu et al. 2015) indicat-
ed that serum and red blood cell TBARS/MDA levels are
significantly higher in depressed patients than in controls
and that antidepressant treatments tended to decrease MDA
levels. These findings indicate increased lipid peroxidation
and as such the results are in agreement with other reports in
depression, including increased levels of oxidized low-density
lipoprotein antibodies (Maes et al. 2011). Interestingly, the
current study found mild correlations between TBARS levels,
on the one hand, and immune biomarkers including sIL-1RA
and sIL-6R (both positively) and sTNF-R1 levels (inversely),
on the other. Previously, it was reviewed that intertwined
activation of oxidative stress and immune-inflammatory path-
ways take part in the pathophysiology of depression (Maes
et al. 2011; Moylan et al. 2014).
The second major finding of this study is that TRD is char-
acterized by increased sIL-6R levels as compared with con-
trols and depressed patients without TRD, lowered sTNF-R2
levels as compared to non-TRD patients and increased
TBARS levels as compared with all other study samples.
Previously, it was shown that increased levels of IL-6 are
associated with TRD (Maes et al. 1997) and that baseline
IL-6 production was significantly lower in treatment re-
sponders; while IL-6 was significantly higher in nonre-
sponders to antidepressants (Lanquillon et al. 2000).
Another study in patients with coronary heart disease and
depression was unable to find that increased serum IL-6 levels
predict a poor response to treatment with antidepressants (Bot
et al. 2011). In an animal model of depression, sustained in-
creases in central nervous system IL-6 may play a
Fig. 2 The mean (SE) values of
all measurements in normal con-
trols (0), patients with depression
without melancholia (1), and
those with melancholia (2). All
data are in z scores computed on
the Ln transformation of the
measurements. IL-1α,
interleukin-1 alpha; IL-1RA, sol-
uble interleukin 1 receptor antag-
onist; IL-2R, soluble interleukin 2
receptor; IL-6R, soluble interleu-
kin 6 receptor; TNF-60/80, solu-
ble tumor necrosis factor receptor
60 kDa/80 kDa; TBARS, thio-
barbituric acid reactive substances
Table 7 Results of automatic logistic regression analyses with
melancholic depression (MEL MDD) versus non-MEL MDD as depen-
dent variable and immune biomarkers, i.e., interleukin-1α, soluble inter-
leukin 1 receptor antagonist (sIL-1RA), sIL-2R, sIL-6R, soluble tumor
necrosis factor receptor 60 kDa/80 kDa (sTNF-R1/R2), and thiobarbituric
acid reactive substances (TBARS), age, gender, drug state, nicotine de-
pendence, and marital status as explanatory variables
Dependent variables Explanatory variables Wald df p Odds ratio lower and upper 95% CI
MEL MDD (versus non-MEL MDD) IL-1α
sIL-6R
PC1
PC2
9.52
11.88
2.53
5.72
1
1
1
1
0.002
0.001
0.112
0.017
0.40
29.27
0.68
1.98
0.23–0.72
4.29–199.76
0.43–1.09
1.13–3.47
PC1, PC2: the first two varimax-rotated PC subtracted from the drug state data
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pathophysiological role underlying treatment resistance to an-
tidepressants (Sukoff Rizzo et al. 2012). These and other data
suggest that IL-6 trans-signaling is associated with treatment
resistance in depression (Maes et al. 2014).
Previous studies reported that baseline serum TNFα levels
were significantly decreased during treatment with antidepres-
sants in a responder group only (Lanquillon et al. 2000). Other
studies, however, were unable to find increased levels of
TNFα in depressed patients with TRD as compared to those
without TRD (Mikova et al. 2001). In the latter study, there
was also a significant association between increased sIL-2R
levels and TRD, a finding which could not be replicated in the
present study. Moreover, previously no significant association
between increased sIL-1RA levels and TRD were found by
Maes et al. (1997). Such discrepancies may likely be ex-
plained by patient selection criteria. Thus depending on the
number of patients suffering from specific depression sub-
types (including melancholia and atypical depression), other
biomarkers may be found to correlate with TRD.
We found that TRD was accompanied by increased levels
of TBARS as compared with non-TRD patients and controls.
To the best of our knowledge, this is a first study showing
increased TBARS/MDA levels in TRD patients. Previous
studies showed increased immunoglobulin (Ig)M responses
to MDA in patients with chronic depression and increased
IgM responses to a number of MDA-related oxidatively mod-
ified membrane markers, including oleic and azelaic acid
(Maes et al. 2013).
The third major finding of this study is that melancholic
depression was accompanied by significantly increased serum
sIL-6R and lowered IL-α levels as compared with non-
melancholic major depression. Increased levels of sIL-6R
were previously reported in depression and post-traumatic
stress disorder comorbid with depression (Maes et al. 1995a,
1999), although the latter studies did not report on a possible
correlation with melancholia. Given that IL-6 levels are in-
creased in major depression (Maes et al. 1995a; Słuzewska
et al. 1995; Frommberger et al. 1997; Liu et al. 2012), the
findings on increased sIL-6R levels in melancholia may sug-
gest that this phenotype is accompanied by increased IL-6
trans-signaling (Maes et al. 2014).
In postmortem brain tissue of depressed patients, increased
IL-1α gene expression was detected by Shelton et al. (2011).
We are not aware of any other data linking lowered IL-1α
serum levels to melancholia, although increased mitogen-
stimulated levels of IL-1β were found in melancholic depres-
sion (Maes et al. 1991). While IL-1α usually functions as an
autocrine growth factor, which only reaches the environment
following cellular necrosis, IL-1β is secreted from activated
immune cells and plays a major role in the initiation and
maintenance of inflammatory responses (Maes et al. 2012c;
Dinarello 2011). Therefore, it is not clear whether the current
results on IL-1∀ may have clinical relevance. The present
study did not show significant associations between atypical
depression and any of the biomarkers. These negative findings
extent those of previous papers showing no significant asso-
ciations in serum IL-6 and TNFα concentrations, although
other cytokines (not measured in our study) may be altered
in atypical depression (Yoon et al. 2012).
The fourth major finding of this study is that an acute ep-
isode of major depression is characterized by increased sIL-
6R levels as compared with the remitted state. Given that an
acute episode of depression is also accompanied by increased
serum IL-6 levels (Maes et al. 1995a; Liu et al. 2012), the
results suggest increased IL-6 trans-signaling occurs in acute
depression. Not all studies, however, were able to find in-
creased serum sIL-6R levels (Rief et al. 2001) or lymphocyte
IL-6R mRNA expression (Rizavi et al. 2016) in depression. It
should be added that we did not find significant associations
between the biomarkers and illness severity. Also, no signifi-
cant associations could be found between any of the bio-
markers and number of depressive episodes. Previous re-
search showed that sensitization may occur in some selected
immune biomarkers, including TNFα, IL-6, IL-1 (α + β), and
sIL-1RA levels. Thus, the number of episodes was significant-
ly associated with increasing levels of TNFα and IL-1 (Maes
et al. 2012b), while greater increases in serum sIL-1RA and
IL-6 were established in puerperal women who had suffered
from a lifetime depression (Maes et al. 2001).
The results of the current study should be interpreted with
regards to its limitations and strengths. Firstly, this is a case-
control study and therefore no causal inferences may be made.
Secondly, it would have been more informative if we had also
measured serum IL-6 and IL-1β and other cytokine levels,
including Th17, T regulatory, and Th2 cytokines. Thirdly,
included were individuals between 21 and 70 years old and,
consequently, our results cannot be generalized to older or
younger populations. Strengths are that we included relevant
phenotypes of major depression, while adjusting our data for
background variables including age, sex, smoking, and the
drug state of the patients.
In conclusion, major depression is characterized by in-
creased sIL-1RA, sTNF-R1, and TBARS concentrations,
while the acute phase of depression is accompanied by higher
sIL-6R levels (compared with the remitted state) and melan-
cholia by higher sIL-6R but lower IL-1α levels. As such,
increased sIL-1RA, sTNF-R1, and TBARS levels may be trait
markers of major depression, while increased sIL-6R levels
may be state markers of melancholia and an acute episode.
These findings show that depression, and especially acute
depression and melancholia, are associated with increased lip-
id peroxidation and immune alterations pointing towards im-
mune activation (increased sIL-6R), increased activity of the
CIRS (increased sIL-1RA), and signs of immunosuppression
(lowered IL-1α and increased TNF-R1/R2 levels). TRD is
accompanied by increased TBARS and sIL-6R but lowered
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sTNF-R2 levels, suggesting that highly increased lipid perox-
idation, immune activation, and lowered immunosuppression
increase risk towards TRD.
As discussed previously, the CIRS response has anti-
inflammatory and negative immunoregulatory effects
thereby protecting against immune-inflammatory re-
sponses (Maes et al. 2012a, 2016). Previously, we have
discussed that targeting immune-inflammatory pathways
in depression by anti-inflammatory drugs is probably not
the best treatment strategy. Indeed, interfering with the
equilibrium between protective (CIRS) and more detri-
mental (increased neurotoxicity by inflammatory cyto-
kines) forces may have many unwanted or unpredictable
consequences (Maes et al. 2016). More precise knowledge
on the immune-inflammatory response in relation to the
CIRS in depression and the impact of the new drugs on
both systems is needed before using drugs that interfere
with their equilibrium. Moreover, lipid peroxidation is—
by far—a more important trait marker of depression and
TRD as compared with the immune biomarkers, suggest-
ing that increased oxidative stress in the primary target.
Finally, since TRD is characterized by increased TBARS
and sIL-6R and lowered sTNF-R2 levels, we may suggest
that increased lipid peroxidation coupled with possible
signs of increased TNFα and IL-6 trans-signaling may
play a role in TRD. Therefore, multi-targeting immune-
inflammatory and oxidative stress pathways may have
therapeutic promise (Maes et al. 2016).
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